A three-agent neoadjuvant regimen that combines a PD-L1 inhibitor with chemotherapy appears feasible for patients with malignant pleural mesothelioma, according to an ongoing phase I trial. The findings [ about neoadjuvant therapy ] were presented at the International Association for the Study of … More
Main Navigation Menu
➤ About the Law Offices of Thomas J. Lamb
PRACTICE AREAS
➤ Asbestos and Mesothelioma Claims
➤ Benzene Diseases and Cancers Claims
➤ Pharmaceutical Drug Injury Lawsuits
➤ Breast Implants Lymphoma Cancer Cases
➤ Philips Breathing Devices Recall Lawsuits
➤ GenX Water Contamination Cancer Cases
➤ Free Case Evaluation by Lawyer Tom Lamb
INFORMATION
➤ Frequently Asked Questions (FAQs)
➤ Medical Records Copying Cost Laws
➤ Client Resources: Legal, Medical, and More
➤ Collection of Articles by Our Law Firm
Please know that you can use our Quick Contact Form to tell us a bit about your case.
Recent Articles
Drug Regulator MHRA Imposes More Xeljanz Use Limitations in October 2021
In this Drug Safety Update document, “Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies”, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) took new regulatory action regarding the Xeljanz risk of cardiovascular events as … More
Nivo/Ipi Combo Now ‘Standard of Care’ in Mesothelioma
The [ combination immunotherapy consisting ] of nivolumab (Opdivo) and ipilimumab (Yervoy) offers a durable, long-term survival benefit over chemotherapy for patients with unresectable malignant pleural mesothelioma (MPM), confirms a 3-year updated analysis of the CheckMate 743 trial. After 3 … More
Imbruvica Heart-Related Side Effects and Cardiotoxicity Safety Issues
In this article, we point out a few of the medical news reports about heart-related Imbruvica side effects that have been published in the past 12 months. First, there is this November 2020 Healio article, “Link between ibrutinib-related hypertension, heart problems necessitates close … More
Access to care varies greatly among patients with malignant pleural mesothelioma
Access to care varied significantly among patients with stage I to stage III malignant pleural mesothelioma, according to study results. The findings — presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer — showed variations in access based on … More
Possible New Xeljanz Side Effect: Peripheral Neuropathy
As reported in this Letters to the Editor item, “Tofacitinib and Risk of Peripheral Neuropathy? Experience of 2 Cases in Patients With Rheumatoid Arthritis”, patients treated with Xeljanz (tofacitinib) for their rheumatoid arthritis (RA) may be at risk of neurological adverse events, such as … More